Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.
After more than 2 years of having our lives disrupted by COVID-19, the opportunity for in-person interaction, communication, and reconnection among colleagues is finally here during the hybrid 10th Annual Meeting of the Society of Hematologic Oncology (SOHO 2022). This hybrid event offers in-person and virtual attendance options.
Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off on September 28-October 1, 2022, with a commitment from meeting organizers to hold the safety of its members and annual meeting attendees in highest regard.
To that end, the SOHO 2022 Safety Plan makes every effort to keep attendees safe and minimize the risk of transmission of COVID-19 by following on-site preventive measures, including physical distance limitations. Attendees will find that throughout the Hilton Americas-Houston, the use of touchless disinfecting stations, equipped with wipes and hand sanitizers, are located strategically on the meeting floor. Further, only those attendees who are fully vaccinated against COVID-19 will be allowed to attend SOHO 2022.
Your first stop when attending the meeting will be to register at the registration desk on level 4 of the hotelto pick up your lanyard and attendee badge. The registration fee for hybrid participants includes access to some in-person sessions, luncheons, meal sessions, exhibitions, poster session, welcome reception, a full-access badge, 1 copy of the final program and abstract proceedings book, the Clinical Lymphoma, Myeloma & Leukemia journal supplement, continuing education credits, and other workshop-related materials.
As you start your day, you might need a quick pick-me-up. Available for your (guilty) pleasure are 2Italian coffee stations, serving up piping-hot espressos, lattes, or café Americano. If they serve biscotti, I am so there!
Although attending the Plenary Sessions is always exciting, if you notice your mobile devices are running low on charge, don’t worry, SOHO 2022 provides a charging station within the Plenary Session meeting room so you don’t miss these important and potentially practice-changing presentations. Thesestations are located throughout this floor, outside of the main conference room.
SOHO 2022 also provides a Wi-Fi lounge area to check emails, update social media accounts, and download the SOHO 2022 mobile app,which isavailable on Google Play and the Apple App Store. Search for “SOHO2022”in the app store to download!
The SOHO 2022 mobile app not only provides a schedule of events, but attendees will also find that it’s highly interactive. For example, audience members may ask questions during the Q&A portions of the program, and submitted questions may be “upvoted” by other audience members, moving the most sought-after questions to the top. In addition, there are several case presentations, debates, and polls during the live, virtual event that are placed inside the mobile app. For the ultimate event experience, SOHO highly recommends all attendees download the SOHO 2022 mobile app.
If you can’t attend a particular session, all is not lost, as most sessions are covered in the SOHO Daily News. This daily newspaper covering the conference provides attendees with salient points from many of the presentations, including physician-written articles from the presenters themselves for a firsthand take on the topic. The SOHO Daily News can be found every day in the daily newspaper bins spread throughout the conference hall.
For many, this will be the first conference attended post pandemic. Although many personal and professional activities were temporarily put on hold, cancer was not. The organizers of SOHO 2022 hope you find the meeting collaborative, efficient, enjoyable, and hypothesis provoking.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More